Hosvilda M 50/500mg Tablet

Hosvilda M 50/500mg Tablet contains Vildagliptin 50mg and Metformin 500mg. It is indicated for management of type 2 diabetes mellitus, a chronic condition affecting blood glucose processing. The medication helps control elevated blood sugar levels and may improve insulin sensitivity in patients with insulin resistance. It can be used to manage blood sugar levels in individuals with overweight and obesity-related metabolic disorders.

Hosvilda M 50/500mg Tablet is contraindicated in patients with known hypersensitivity or allergy to Vildagliptin, Metformin, or any inactive ingredient in the formulation. It should not be used in patients with severe renal impairment (creatinine clearance below 30 mL/min), as the kidneys are the primary route of excretion and clearance is reduced in renal dysfunction. Patients with a history of ketoacidosis, diabetic ketoacidosis, or lactic acidosis should not use this medication. It is not recommended for patients with severe hepatic impairment.

Conditions associated with tissue hypoxia are contraindications, including heart failure, respiratory failure, recent myocardial infarction, and shock. In patients requiring iodinated contrast agents for radiological procedures, this medication should be discontinued before or at the time of the procedure and not restarted until at least 48 hours after, provided renal function has been re-evaluated and confirmed to be stable.

Elderly patients may be more susceptible to adverse effects of this medication, particularly those related to renal function. Regular monitoring of kidney function is essential in this population. Hosvilda M 50/500mg Tablet is not recommended for use in children.

Management of type 2 diabetes mellitus Control of hyperglycemia Improvement of insulin sensitivity Weight management

Hosvilda M 50/500mg Tablet works by combining the mechanisms of its two active ingredients, Vildagliptin and Metformin, to manage type 2 diabetes mellitus. Vildagliptin functions by inhibiting the enzyme DPP-4, which increases active incretin hormone levels, stimulating insulin secretion and reducing glucagon release. Metformin reduces hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity through AMPK activation. This combined action helps regulate blood sugar levels through complementary pathways.

Hosvilda M 50/500mg Tablet is administered orally as tablets. The recommended starting dosage and any necessary dose adjustments are determined based on the specific condition being treated and the patient's response to the medication.

Hosvilda M 50/500mg Tablet causes some side effects like all medications, although not everyone will experience them. Serious Lactic acidosis Severe allergic reactions Common Gastrointestinal disturbances Hypoglycemia Headache Dizziness Weakness or fatigue Metallic taste in the mouth

Regularly check kidney function as Hosvilda M 50/500mg Tablet is eliminated through the kidneys. Be cautious of low blood sugar levels, especially when taking other diabetes medications. Watch for symptoms of lactic acidosis and seek immediate medical help if experienced. Temporarily stop medication before using contrast agents for medical tests. Use with care in patients with liver problems and be mindful of any signs of infection. Inform healthcare providers about the medication before any surgery or medical procedures. Be aware of potential allergic reactions and report any promptly. Monitor for vitamin B12 deficiency during long-term use and consider supplementation if needed. Stay hydrated, especially during illness or in hot weather, to prevent dehydration complications. Consult a healthcare provider for any changes in management during periods of stress, like surgery or infections. Use with caution during pregnancy and lactation, and discuss potential risks and benefits with a healthcare provider.